Comparison of Proteostasis Therapeutics Inc. (PTI) and Unum Therapeutics Inc. (NASDAQ:UMRX)

Since Proteostasis Therapeutics Inc. (NASDAQ:PTI) and Unum Therapeutics Inc. (NASDAQ:UMRX) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation of both companies.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Proteostasis Therapeutics Inc. 1 8.19 N/A -1.58 0.00
Unum Therapeutics Inc. 3 5.02 N/A -1.33 0.00

Table 1 demonstrates Proteostasis Therapeutics Inc. and Unum Therapeutics Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows the return on assets, return on equity and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Proteostasis Therapeutics Inc. 0.00% -84% -64.7%
Unum Therapeutics Inc. 0.00% -62.3% -43.3%

Liquidity

The Current Ratio and Quick Ratio of Proteostasis Therapeutics Inc. are 11.3 and 11.3 respectively. Its competitor Unum Therapeutics Inc.’s Current Ratio is 2.7 and its Quick Ratio is 2.7. Proteostasis Therapeutics Inc. can pay off short and long-term obligations better than Unum Therapeutics Inc.

Insider and Institutional Ownership

Proteostasis Therapeutics Inc. and Unum Therapeutics Inc. has shares owned by institutional investors as follows: 60.5% and 47.8%. About 0.3% of Proteostasis Therapeutics Inc.’s share are owned by insiders. Competitively, Unum Therapeutics Inc. has 39.76% of it’s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Proteostasis Therapeutics Inc. -9.53% -15.14% -23.06% -72.83% -64.36% -74.59%
Unum Therapeutics Inc. -11.61% -17.84% -39.26% -50% -87.48% -55%

For the past year Proteostasis Therapeutics Inc. was more bearish than Unum Therapeutics Inc.

Summary

Unum Therapeutics Inc. beats on 5 of the 7 factors Proteostasis Therapeutics Inc.

Proteostasis Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics that treat diseases caused by dysfunctional protein processing, such as cystic fibrosis. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class that is in Phase-I studies. The company is also developing PTI-801, a corrector molecule; PTI-808, a potentiator molecule; and unfolded protein response (UPR) modulators that are in preclinical development. It has collaboration with Astellas Pharma, Inc. to research and identify therapies targeting the Unfolded Protein Response (UPR) pathway. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Unum Therapeutics Inc., a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma. The company's product portfolio also includes ACTR707 used in combination with rituximab that is in Phase I clinical trials to treat adult patients with r/r B cell non-Hodgkin lymphoma; ACTR087 used in combination with SEA-BCMA, which is in Phase I clinical trials for treating patients with r/r multiple myeloma; and ACTR707 used in combination with trastuzumab, which is in late preclinical development phase for treating HER2+ solid tumor cancers. It has strategic collaboration with Seattle Genetics, Inc. to identify, research, develop, and commercialize antibody-coupled T cell receptor therapies. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.